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Peritoneal carcinomatosis (PC) is generally considered a lethal disease, with a poor prognosis. Cytoreductive surgery (CRS) with
hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a new approach for peritoneal surface disease. This study
investigated theearlyexperience withthis combinedmodality treatmentatasingleinstitute.FromJanuary2007toMarch2010, 24
patients were treated After aggressive CS, with HIPEC (cisplatin 25mg/m2/L and mitomycin C 3.3mg/m2/L was administered for
90-minutesat40.5◦ C).ThesedatasuggestthataggressiveCRSwithHIPECforthetreatmentofPCmayresultinlowmortalityand
acceptable morbidity. Rigorous patient selection, appropriate and prudent operative procedures were associated with encouraging
results in our experience.
1.Introduction
The term peritoneal carcinomatosis (PC) was ﬁrst used
by Sampson in 1931 to describe a common manifestation
of tumor progression in gastrointestinal and gynecologic
malignancies [1]. PC is characterized by the presence of
numerous tumour nodules of various sizes that are dis-
tributed throughout the abdominal-pelvic cavity. As the
disease progresses, the nodules become conﬂuent to form
plaques, masses, or uniformly cover peritoneal surfaces.
The same clinical picture may be seen in rare primary
peritoneal tumors, such as peritoneal mesothelioma and
serous-papillary peritoneal (extraovarian) carcinoma [2].
Until recently, PC has been considered a systemic
metastatic condition with extremely poor prognosis and no
standard therapy. These patients are generally managed by
supportive or palliative care and systemic chemotherapy.
The role of surgery has been traditionally limited to the
palliation of bowel obstruction or painful tumor masses,
with unsatisfactory results in terms of survival beneﬁt,
quality of life, or disease control. In large historical series,
a median survival of 5–7 months has been reported for
patients with PC of colorectal origin and about 3 months for
patients with PC of gastric origin [3, 4].
In the last two decades, better understanding of the
natural history and biology of PC has occurred. The
evidence that the disease remains frequently conﬁned to
the peritoneal surface with no hepatic or distant metastases
has evolved into an aggressive clinical approach focused
on providing the greatest overall beneﬁt for these patients.2 ISRN Oncology
Cytoreductive surgery (CRS) with hyperthermic intraperi-
toneal chemotherapy (HIPEC) is a multimodality treatment
aiming at complete disease eradication through the surgical
cytoreduction of all the visible tumor in combination with
HIPEC, to eradicate the microscopic residual disease [5, 6].
Although pseudomyxoma peritonei is a locally aggressive
not metastasizing condition originating from low-grade
appendiceal neoplasms, long-term survival of only 20–
30% has been reported after debulking surgery and pallia-
tive chemotherapy. With the advent of the local-regional
approach, ﬁve-year and median survival have increased to
52–96% and 51–156 months, respectively [7]. This has
stimulated the use of CRS and HIPEC in other peritoneal
surface malignancies. Several centers have reported a median
survival improvement up to 34–92 months for peritoneal
mesothelioma and up to 38–62 months for colorectal cancer
PC [8–11]. In stage-III ovarian cancer, complete surgical
cytoreduction has been shown to be closely related to
survival and a phase-III study has demonstrated the survival
beneﬁt of intraperitoneal versus intravenous chemotherapy,
resulting in a growing interest for the use of the combined
treatment in this clinical setting [12–14].
Due to treatment complexity, CRS with HIPEC is as-
sociated with high operative morbidity and signiﬁcant
economic costs. As a consequence, the slow diﬀusion of
this technique in many countries precludes most patients
from being referred for appropriate treatment [15, 16].
The National Cancer Institute (INCAN) in Mexico City is
a comprehensive cancer centre and the national reference
institution for oncology research and clinical practice. We
started our peritoneal surface malignancy program in Jan-
uary 2007. This current study was carried out to critically
analyze the morbidity and mortality of our initial experience
with cytoreductive surgery and HIPEC. Additionally, patient
survival was assessed as secondary end-point. These early
results are presented in an attempt to document the eﬀorts
required to initiate, develop, and maintain a peritoneal
surface malignancy management unit, with the hope that
such an experience may be of help to others.
2.MaterialandMethods
All patients were treated following a feasibility protocol
approved by the Institutional Scientiﬁc Committee and
Bioethics Committee. An informed consent form was signed
by all patients. The trial started in January 2007.
2.1. Patient Selection. Eligibility criteria for combined treat-
ment the were the following:
(1) clinical, radiological, or pathological diagnosis of
peritoneal carcinomatosis,
(2) age 18 to 75 years,
(3) noconcomitantsevereheart,respiratory,liver,hema-
tologic, or kidney diseases,
(4) functional status of 0–2 according to the Eastern
Cooperative Oncology Group (ECOG),
(5) absence of hepatic or extra-abdominal metastatic
disease,
(6) PC amenable to potentially complete surgical cytore-
duction at preoperative computed tomography scan.
Evaluation for suitability to undergo CRS and HIPEC was
madeduringmultidisciplinarymeetingsattendedbysurgical
oncologists, medical oncologists, radiologists, cancer care
nurses, and research staﬀ.
2.2. Cytoreductive Surgery. T h eg o a lo ft h es u r g i c a lc y t o r e -
duction was to remove all the visible disease, according
to the technique originally described by Sugarbaker [6].
Brieﬂy, with the patient in a supine position, a xiphoid-
pubic midline incision was made. The cavity was reviewed to
determine the extent of disease and feasibility of a complete
cytoreduction. The “peritoneal cancer index” (PCI), which
integrates size and distribution in the peritoneal surface,
was used to determine the extent of the tumour [17]. In all
patients,thediagnosisofPCwasconﬁrmedbyfrozensection
pathological examination; peritoneal lavage for cytology was
performed using 400mL sterile solution (100mL in each
quadrant).
The cytoreductive surgical procedures included one or
more of the following steps, depending on the extent of
disease:
(1) greater omentectomy, right parietal peritonectomy
and right colon resection,
(2) pelvic peritonectomy, resection of the sigmoid colon
with total abdominal hysterectomy and salpingo-
oophorectomy in women,
(3) omentectomy, extensive dissection of the hepatic
ligament, cholecystectomy with or without gastric
antrectomy,
(4) right upper quadrant peritonectomy and Glisson’s
capsule resection,
(5) left upper quadrant peritonectomy and splenectomy,
(6) other intestinal resection and/or abdominal mass
resection.
Completeness of cytoreduction (CCR) was classiﬁed at the
end of the surgical phase according to Sugarbaker criteria, as
macroscopicallycomplete (CCR-0); optimal: residual disease
≤2.5mm in any region (CCR-1); or grossly incomplete:
residual disease >2.5mm (CCR-2) or >25mm (CCR-3) [17].
2.3. HIPEC Technique. HIPEC was performed at the end
of the surgical cytoreduction and after the completion of
bowel anastomoses, with veriﬁcation of haemostasis. Only
patients who were able to be completely or optimally cytore-
duced, with no retroperitoneal nodal involvement, with
hemodynamically stable conditions at the end of the surgery
and did not suﬀer of major intraoperative complications,
underwentHIPEC.Sinceapossibleadverseeﬀectofheatand
local-regional chemotherapy has been reported, HIPEC was
performed only in patients receiving not more than 2 bowel
anastomoses.ISRN Oncology 3
Table 1: Characteristics of the study patients.
Age, average (range) 55.4 (26–68)
Gender
Female, 20 (87.5%)
Male 4 (12.5%)
Primary site
Ovarian epithelia cancer 10
Colorectal 6
Appendix 3
Pseudomyxoma 3
Gastric 2
Previous surgery 24 (100%)
Previous systemic chemotherapy 21 (87.5%)
Tumours 10 yes (42%): CEA
marker 14 No (58%)
Four in-ﬂow catheters were placed in each abdominal
quadrant. A ﬁfth out-ﬂow catheter was placed in the
central abdomen to collect the perfusate. Chemotherapy
agents used were mitomycin-C (3.3mg/m2/L) and cisplatin
(25mg/m2/L) for 90 minutes [18]. The HIPEC was con-
ducted according to the closed-abdomen technique in 23
patients, with temporary closure of the skin and reopening
of the abdomen at the end of the perfusion for checking
the whole cavity before deﬁnitive closure. In one patient,
the procedure was performed according to the Coliseum
technique, by elevating the skin edges and covering the open
abdominal cavity with a plastic sheet. An extracorporeal
circulation device with a heat exchanger was used. Perfusate
volume was 3-4L. The perfusion solution was kept at an
average of 41◦C(range40–43◦C).Intracavitary,out-ﬂowand
in-ﬂow catheter temperatures were continuously monitored.
Once the temperature was uniform in all quadrants, the total
dose of the chemotherapy was fractionated in 3 portions:
50%, 25%, and 25%.; this dose was perfused 30 minutes each
one.
2.4.Statistics. C ontin uousvariablesw er ee xpr essedasmeans
and range, and categorical variables as frequency and
percentages. In operative morbidity analysis, both surgi-
cal complications and systemic toxicity related to local-
regional chemotherapy were considered. Postoperative com-
plications occurring within 30 days of the procedure were
scored according to the National Cancer Institute Com-
mon Terminology Criteria (http://ctep.cancer.gov/forms/
CTCAEv3.pdf). The following independent variables were
taken into consideration for potential association with major
surgical complications: primary tumor histology, gender,
functional status, age, body mass index, prior chemotherapy,
prior radiotherapy, duration of procedure, and the extent
of cytoreduction. Survival curves were estimated using the
Kaplan-Meier method [19]. The log-rank test was used to
compare overall survival data. Statistical signiﬁcance was
deﬁned as P<0.05. Statistical analyses were performed
Table 2: Complications.
Complications
9 cases (37%)
2 bleeding
1 pneumonia 1 F´ ıstula
1 acute renal failure
4 diaphragm opening
15 no (%)
Reoperation 2 cases (8.33%) Bleeding into the operated site
Intensive care
13 yes (54%) 1 bleeding
5e x t e n d e ds u r g e r yt i m e
11 no (46%) 4 diaphragm opening
Mortality 0 No
using the Statistical Package for the Social Sciences software
(version 15.0; SPSS, Chicago, IL, USA).
3. Results
From January 2007 to March 2010, a total of twenty-four
combined procedures were performed in 20 women and
four men. Primary cancer was epithelial ovarian cancer in
ten cases, colorectal cancer in six, appendiceal carcinoma in
three, gastric cancer in two, and three patients had pseu-
domyxoma peritonei originating from low-grade mucinous
tumor. Patient characteristics are summarized in Table 1.
3.1. Operative Outcomes. Average operative time was 402
minutes (range of 350–640 minutes). The average blood loss
volume was 938mL, ranging between 100 and 3700mL with
an average transfusion of 3 packages of red blood cells per
patient (range 1–5).
Thefollowingintraoperativecomplicationsoccurredand
were managed during the operation: diaphragm opening
(n = 4) and intestinal perforation (n = 1) requiring
immediate repair.
Thirteen of the 24 patients (54%) included in the study
required postoperative admission to the intensive care unit
(ICU). The average length of stay in ICU was 1.7 days (range
of 1–13 days). The average length of stay in hospital was 8.2
days (range of 5–19 days).
Major postoperative complications (Table 2)( g r a d e s3 -
4) occurred following 5 combined procedures (20.8%),
including bleeding (n = 2), pneumonia (n = 1), ﬁstula
(n = 1), and acute renal failure (n = 1). Return to the
operation theater for control of postoperative bleeding was
needed in two patients, accounting for a reoperation rate of
8.33%. No operative death occurred.
3.2. Survival and Failures. For the overall series, median
followup was 15.5 months (range 3–36). The Kaplan-Maier
estimated survival of the entire series is shown in Figure 1.A t
the end of the study period, 22 patients were alive and 2 died
for disease-related causes, accounting for a median survival
of 28 months.4 ISRN Oncology
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Figure 1: Overall survival of the entire study group.
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Figure 2: Overall survival according to primary tumor.
In a subgroup analysis, all the patients with pseudomyx-
oma peritonei (n = 3), gastric cancer (n = 2), and appendi-
ceal carcinoma (n = 3) were alive at a median of 25, 11,
and 8 months, respectively. Among patients treated for PC
of colorectal cancer, four are currently alive at a median
of 11 months and two died at 11 and 12 months from
CRS and HIPEC. Finally, as patients with epithelial ovarian
cancer are concerned, eight are currently alive at a median
of 20 months and two died at 12 and 24 months from
combined treatment. Overall survival curves according to
primary tumor are shown in Figure 2.
4. Discussion
Cancer is a severe public health problem, and peritoneal
carcinomatosis is one of the most common cause of death
in patients aﬀected by intra-abdominal cancers [6]. PC is
diagnosed in 8–10% of cases at the time of the initial
diagnosis of primary colorectal tumor, and in 13–30% of
patients with recurrent disease; in 25–35% of cases, PC
is conﬁned exclusively to the peritoneum [20]. Gastric
cancer is still an important gastrointestinal malignancy
worldwide, especially in developing country. Peritoneum
is the ﬁrst site of treatment failure in up to 40–50% of
patients [10]. Epithelial ovarian cancer is diagnosed at an
advanced stage in up to 75% of women, with peritoneal
involvement and/or distant or nodal metastases (Interna-
tional Federation of Gynecology and Obstetrics stage III/IV)
[12].
Conventional treatment options for PC, such as sup-
portive care, palliative or debulking surgery, and systemic
chemotherapy, do not provide adequate beneﬁt to these
patients [3, 4]. With this in mind, researchers have been
working during the last decades on an innovative combined
treatment modality. In 1982, Pestieau and Sugarbaker pro-
posed the management of PC by peritonectomy procedures
and multivisceral resections to maximally cytoreduce the
macroscopic disease, in combination with intraperitoneal
hyperthermic chemotherapy to treat the residual micro-
scopic disease [21]. CS creates the optimal environment
for intraperitoneal chemotherapy, and local-regional drug
administration results in higher intraperitoneal concentra-
tions and minimal systemic toxicity. The intraoperative
time setting allows optimal distribution throughout the
abdominal cavity before the development of postoperative
adhesions. Finally, mild hyperthermia has both intrinsic
and synergistic eﬀects with platinum compounds and
mitomycin-C. Taken together, these concepts represent the
rational bases of comprehensive treatment [5, 6].
Several independent trials of CRS and HIPEC have
reported a dramatic survival improvement in selected
patients with peritoneal surface malignancies [7–11, 14].
Furthermore, three comparative studies have demonstrated
the superiority of the combined approach over conventional
therapies in the treatment of colorectal cancer PC. In a
randomized trial, median survival was 23 months with CS
and HIPEC and 12.6 months with ﬂuorouracil/leucovorin-
based systemic chemotherapy (P = 0.0032) [22]. In a French
retrospective controlled study, median survival was 23.9
months with modern systemic agents and an unprecedented
62.7 months with optimal cytoreduction and HIPEC (P<
0.05) [23]. Finally, Franko et al. has recently reported a
median survival of 34.7 months in 67 patients treated with
CRS and HIPEC, as compared to 16.8 months in a matched
control group managed by modern systemic chemotherapy
± biological agents (P<0.001) [24].
CRS and HIPEC is a complex procedure involving
extensivestrippingoftheperitonealsurface,multiplevisceral
resection, up to 4-5 bowel anastomoses, and high-dose
chemotherapy under hyperthermic conditions. Operative
time of 10–14 hours is the rule [7–11]. High rates of poten-
tiallylife-threateningcomplicationshavebeenreportedbyall
the centres managing these patients [25]. Reported morbid-
ity and mortality rates vary widely from 12% to 67.6% and
0%to9%,respectively.Themostcommonadverseeventsare
intestinal perforations, anastomotic dehiscence, intestinal
ﬁstula, bile leak, postoperative bleeding, and pancreatitis;
in addition to the usual major surgical risks: deep veinISRN Oncology 5
thrombosis, pulmonary embolism, pneumothorax, myocar-
dial infarction, bone marrow aplasia, and haematological
toxicity. The complications may be secondary to surgery,
hyperthermia, and chemotherapy.
This paper describes the initial experience with peri-
tonectomy and intraoperative intraperitoneal chemother-
apy infusion in a Mexican tertiary referral center. In the
current series, morbidity rate was 20.8% with 5 patients
who developed complications. No operative death occurred.
The adverse event rate in the current study is in line
with that reported by the international centers performing
the combined procedure [25]. Recent reports suggest that
the initial high morbidity associated to CRS and HIPEC
decreases with increasing experience. This is most marked
in specialized centers and includes improvements in patient
selection, surgical expertise, and postoperative management.
This phenomenon has been termed “learning curve” and
reﬂectsthediﬃcultiesinreachingahighlevelofperformance
in demanding surgical procedures [25–27].
Moran analyzed the factors that inﬂuenced the learning
c u r v ef o rC R Sa n dH I P E Cp r i m a r i l yf o rP M P[ 26, 27]. The
ﬁrst 100 patients treated were divided into 3 numerically
equal groups of 33, 33, and 34, respectively. Thus, his 6-
year experience was divided into 3-time intervals of 79, 16,
and 9 months. Both major morbidity and mortality fell
with increasing experience, with anastomotic leakage and
reoperation for bleeding occurring predominantly during
theinitialperiod.Anastomoticleakratefellfrom12%to0%,
and reoperation forbleeding from 15% to 0% over the whole
6-year period.
In our experience, patient selection through periodic
multidisciplinary meetings has been an important element
in reducing complication rates during the initial phase.
The involvement of experienced surgeons, as well as other
health care specialists, has been eﬀective to facilitate training,
experience, and the management of adverse events. Further-
more, knowledge of the toxicity of HIPEC, in particular
the increased risks of anastomotic leakage likely related to
hyperthermic chemotherapy, has resulted in a low threshold
for dose modiﬁcation and even withdrawal from HIPEC, in
patients at high risk of perioperative morbidity or mortality.
Finally,rigorousdatacollectionhasbeenessentialtofacilitate
service improvement and improve the safety of a high-risk
intervention such as CRS with HIPEC.
There have been varying morbidity and mortality rates
in published data [2]. This may be in part explained by the
diﬀerenceamonggroupsintermsofeligibilitycriteria,surgi-
cal aggressiveness, technical skills, modality of delivering the
local-regional chemotherapy and the lack of a standardized
adverse event classiﬁcation and scoring system. In 1999,
Stephens et al. carried out a study involving 200 patients
and reported 27% morbidity with 6% peripancreatitis, and
a mortality of 1.5% [28]. In 2006, Smeenk et al. [29]
reported 54% toxicity and 3% mortality in 103 procedures
of pseudomyxoma peritonei. A univariate analysis found
statistical signiﬁcance between toxicity and age, perforation
of the small intestine, and abdominal tumor burden. In the
current study, in agreement with previously published data,
greater morbidity was found in patients with bulkier disease
who required longer operating time and in whom there was
more bleeding [9, 11, 23–25].
In conclusion, our data demonstrated that an appropri-
ately rigorous approach to CRS and HIPEC may result in
the initiation and development of a new service with low
mortality, acceptable morbidity and encouraging survival
results. Great attention to patient selection, team work
awareness of technical complexity, knowledge of the most
common morbidity patterns, and willingness to learn from
established units have been eﬀective in improving the
learning curve.
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